A Midtown-based medical device startup is carving a niche in the growing field of treatments to address chronic lung disease.
The study, involving five patients, demonstrated the procedural efficiency and feasibility of AerWave's technology.
Company has also raised $12 million in funding led by Lucius Partners NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- AerWave Medical, a leader in ultrasound-based interventional pulmonary solutions ...
AerWave Medical has concluded the feasibility study of its ultrasound lung denervation therapy, designed to treat chronic obstructive pulmonary disease (COPD) and asthma. The first-in-human study ...
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- AerWave Medical , a leader in ultrasound-based interventional pulmonary solutions, today announced the successful completion of its first-in-human (FIH ...
Company has also raised $12 million in funding led by Lucius Partners NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- AerWave Medical, a leader in ultrasound-based interventional pulmonary solutions, ...